The Peptide Field. Teduglutide: approval and evidence record.

Editorial review: 2026-07-23. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/teduglutide

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=teduglutide#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: Teduglutide is a 33-amino-acid GLP-2 analog. In the United States, Gattex (teduglutide) is FDA-approved for people age 1 and older who have short bowel syndrome and depend on fluids or nutrition given through a vein.

Exact product limits: Gattex evidence applies to a specific monitored prescription product. Gattex is a labeled prescription product used with structured monitoring. Its evidence does not establish general gut healing or equivalence for compounded GLP-2 analogues.

Human outcomes: Strong. Randomized trials support reduction in parenteral-support requirements for short bowel syndrome.

Body effects in people: Strong. Intestinal absorption, exposure, and product effects are characterized in the label and trials.

What the evidence shows: Randomized trials found that some participants needed less fluid or nutrition through a vein. The product label defines required screening and ongoing monitoring.

What remains unknown: The evidence does not establish broad treatment of leaky gut, inflammatory symptoms, wellness, or mucosal repair in people without the labeled syndrome.

Safety limits: This monitored prescription therapy has serious risks, including possible acceleration of neoplastic growth. No dosing, reconstitution, or self-treatment guidance is provided.

Product record: Gattex. Form: Powder and diluent for injection. Route: Subcutaneous.
Scope: Short bowel syndrome with parenteral-support dependence in the adult and pediatric populations defined in the label.
Published label: 2025 label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. GATTEX (teduglutide) prescribing information. 2025. Accessed 2026-07-23. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf

PubMed · Gastroenterology. Teduglutide reduces parenteral support in short bowel syndrome. 2012. Accessed 2026-07-23. https://pubmed.ncbi.nlm.nih.gov/22982184/

U.S. Food and Drug Administration. Teduglutide orphan drug designation and approval. 2019. Accessed 2026-07-23. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=126999

Keep the limits, review date, and sources with this record. Check the current source for changes.